p53

Using an algorithm known as HotNet2, an international team has identified more than a dozen genetically altered sub-networks in thousands of tumor samples assessed for the Cancer Genome Atlas project.

FDA Approves Phase I Study Design for Cellceutix's Anti-Cancer Drug Kevetrin

An expanded license with Dana-Farber Cancer Institute for an offshoot of its Cold-PCR technology allows Transgenomic to develop kits that can detect mutations in common cancer-related genes such as KRAS and P53 directly from blood samples and then analyze the variants using multiple sequencing approaches.

The data, while preliminary, suggests that the drug might require a companion diagnostic to establish p53 status prior to treatment, company officials said.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.